Buying a Pharmacy
Why Searchers Look at Pharmacies
Independent community pharmacy is a large, fragmented market under visible stress, which cuts both ways. NCPA's 2025 Digest counts 18,960 independent locations (about 36% of US retail pharmacies) doing a combined $103 billion, with the average store filling roughly 217 prescriptions a day on $5.4 million of sales. Demand is chronic-medication demand: recurring, local, and referral-fed. Chain closures keep sending patients to independents, and many owners are pharmacists near retirement. The stress is real too: 2024 brought a ten-year low in gross profits, and the margin story below is the whole thesis. One more wall to know: North Dakota alone requires majority pharmacist ownership.
What Pharmacies Trade For
The trade body's own deal calculator prices a going concern at an EBITDA multiplier of 3 to 3.5, applied to EBITDA plus half the owner's salary with inventory added at cost; its worked example puts a $3.9M store earning $270,000 at $1,268,000. The trade body's magazine gives no retail EBITDA multiple at all, reserving 5x for compounding and 5x to 6x for long-term care. The publisher's sold pharmacy listings run wider, half of transactions between 1.69x and 3.75x SDE across 2021 to 2025 on a 2.45x median, with a $325,000 median sale price. Two deal shapes exist: a whole-store purchase, and a script-file sale in which a buyer acquires the prescription files and inventory while the location closes. Inventory moves the total check either way.
Reimbursement Decides the Margin
A pharmacy's gross margin is set mostly by parties who never enter the store: pharmacy benefit managers and government programs. NCPA reports 52% of independent prescriptions ride Medicare Part D or Medicaid, and 2024 gross profits hit a ten-year low, with some scripts reimbursed below acquisition cost. Industry reporting credits the 2024 Medicare change with moving DIR adjustments to the point of sale, ending the months-later clawbacks, but the compression itself did not reverse. Diligence the margin per script by payer, not the blended number: a store can grow scripts and shrink profit at the same time.
The Script File Is the Asset
What transfers in a pharmacy sale is a book of patients and their refills, and it moves on trust and continuity. Verify the file's trend (script counts, transfers in and out, refill persistence), because a declining file at a strong multiple is an overpriced deal wearing a good year. Continuity of the pharmacist-in-charge matters to both patients and the state board; every state requires one, and the license transfer sequence (state permit, DEA registration, NCPDP and NPI updates, payer contracting) has to be mapped before closing or the store cannot bill. The primary wholesaler agreement carries rebate tiers and purchase commitments worth reading line by line.
What to Verify in Diligence
The record to assemble before the offer holds:
- Gross profit per script by payer, with below-cost reimbursements flagged
- Three years of script counts, transfers in and out, and refill persistence
- PBM network contracts and any audit or clawback history
- The primary wholesaler agreement: rebate tiers, commitments, term
- DEA compliance record and controlled-substance inventory reconciliation
- Inventory count at cost, return-to-stock habits, and expired stock
- Front-end, DME, and compounding revenue shares
Financeability Notes
Pharmacies finance under SBA 7(a), and the $1.1M median acquisition loan in the FOIA data sits squarely in searcher range, but lenders underwrite the reimbursement risk directly: expect questions on payer mix, per-script margin trend, and who the pharmacist-in-charge will be on day one. The seasoned charge-off rate for the industry runs higher than its steady-demand reputation suggests, which is the margin compression showing up in loan files. Inventory wants a working-capital line sized to real days on hand. In North Dakota, confirm the pharmacist-majority ownership structure before anything else is spent.
Terms in This Industry
Front-end share
Revenue from everything that is not a prescription, at a margin the prescriptions do not carry.
DIR fees
Money a benefit manager takes back from the pharmacy weeks after a prescription is filled.
PBM (pharmacy benefit manager)
The middlemen who set what a pharmacy is paid for each prescription it fills.
Generic dispensing rate
The share of prescriptions filled with generics, where nearly all of the margin lives.
Closed-door pharmacy
A pharmacy dispensing only to a defined population, such as a facility's residents, never walk-ins.
Transfer-day inventory
The count of controlled stock taken on the day of closing, closing one book and opening another.
Pseudoephedrine logbook
The federal record and daily limit a pharmacy keeps on cold medicine sold from behind the counter.
What the Data Says
Sold-pharmacy benchmarks on BizBuySell run a $325,000 median sale at 2.79x average earnings and 0.42x revenue. The wide gap between the $1.3M median revenue and the median sale is the script-margin problem priced in, and it is why the guide reads reimbursement before anything else.
Source: BizBuySell, pharmacy valuation benchmarks (2021-2025 sold listings)
NCPA's 2025 Digest counts 18,960 independent pharmacy locations, about 36% of US retail pharmacies, in a $103 billion market. They average $5.41 million in annual sales and roughly 217 prescriptions a day, with 52% of scripts under Medicare Part D or Medicaid, and 2024 gross profits at a ten-year low.
Source: NCPA, 2025 Digest Report
North Dakota is the only state requiring pharmacies to be majority-owned by licensed pharmacists (a 1963 law voters kept in place by defeating 2014's Measure 7), so a non-pharmacist buyer needs a compliant structure or a different state.
Enter earnings to apply this industry's cited band.
A sanity check against asking prices, not a valuation.
Lender context, from the SBA loan-level file: Live Oak Banking Company (118), First Financial Bank (AR) (77), Byline Bank (23) wrote the most of this industry's 352 acquisition approvals. A bank that knows the trade says yes faster; the ranking for every industry is on Most Active Lenders by Industry.
Holding a live deal in this industry? Underwrite it with the comps, cited band, and charge-off rate pre-loaded.
Compare bands across industries in the cited multiple bands by industry.
Who Else Is Buying in This Industry
- Guardian Pharmacy Services · Atlanta
Long-term care pharmacies serving assisted living, memory care, hospice, and behavioral health, acquired one and two at a time, the consolidator an LTC-focused pharmacy searcher meets first.
- Wellness Concepts · 2026 · A Grottoes, Virginia long-term care pharmacy serving assisted-living, skilled-nursing, and behavioral-health communities.
- 2 more confirmed on the firm's profile
- Tarrytown Expocare Pharmacy · Austin, Texas
An Austin pharmacy built for group homes and behavioral health providers, buying closed-door long-term care pharmacies to reach thirty-one states from eleven regional sites.
- Embrace Healthcare · 2026 · A closed-door long-term care pharmacy serving IDD providers in Ohio.
- 1 more confirmed on the firm's profile
- SIG Partners · Dallas, TX · runs a searcher program
A family-owned Dallas holding company that has bought more than thirty-seven businesses and dates every close on its own portfolio page, buying to hold rather than to exit.
- Gaddy Drug · 2025 · A Muskogee, Oklahoma pharmacy founded in 1949, running prescriptions, refills and deliveries for its own community.
- 1 more confirmed on the firm's profile
Buyers is the shelf these come from, ordered by who closed something most recently.
How Big This Market Is
There are about 41,792 businesses in this industry. 34,046 of them (81%) have 5 to 99 employees: the band big enough to have something to sell, small enough to finance. Most of the rest are owner-operators with a job rather than a business to hand over.
Census County Business Patterns (2023). How often they change hands, and where they concentrate, is in Market Depth.
Who the Law Lets Own This
North Dakota alone requires majority pharmacist ownership; every state requires a licensed pharmacist-in-charge on the permit.
How buyers structure around it: Non-pharmacist buyers keep a compliant pharmacist-in-charge and, in North Dakota, a pharmacist-majority structure or a different state.
Licensing is set state by state and changes, so confirm the current rule with the state board and your attorney before it shapes an offer. Every trade with a recorded rule is on Ownership & License Rules.
What It Costs to Replace the Owner
The multiples above are quoted on SDE, which adds the owner's pay back into earnings, so they hold only if you do the owner's job. Hire someone instead and the going rate for the role comes back out. For this trade that is usually the pharmacist the license requires on site, paid a median of $140,910 a year nationally. Subtract it from SDE before applying any multiple, because at a 3x multiple that wage also takes about $422,730 off what the business is worth to you.
Pharmacists, BLS Occupational Employment and Wage Statistics (2025), national, all industries, before payroll taxes and benefits. Every role, and the same arithmetic worked end to end, is in Manager Wages.
How Often These Loans Go Bad
Of the 136 SBA acquisition loans in this industry that are old enough to have failed, 5 were charged off: a rate of 3.68%. Across every industry we can measure, the pooled rate is 4.20%, so this one runs cooler than the average acquisition.
Computed from SBA loan-level data on a seasoned cohort. It counts loans already written off, so read it as a floor and as a ranking. Every industry's rate.
The Numbers That Run This Business
- Scripts filled per day, new versus refill
- Gross profit per script by payer
- Scripts reimbursed below acquisition cost
- Transfers in and out of the file
- Front-end and DME sales share
- Inventory days on hand at cost